Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

559 ARTÍCULOS , VIENDO DEL 136 AL 150

Therapeutic potential of glutaminyl cyclases: Current status and emerging trends

Coimbra JRM, Moreira PI, Santos AE, Salvador JAR.

Drug Discov Today. 2023 Oct;28(10):103644. doi: 10.1016/j.drudis.2023.103644. Epub 2023 May 26.

Therapeutic Potential of Nanomedicine in Management of Alzheimer's Disease and Glioma

Anwar F, Al-Abbasi FA, Naqvi S, Sheikh RA, Alhayyani S, Asseri AH, Asar TO, Kumar V.

Int J Nanomedicine. 2023 May 22;18:2737-2756. doi: 10.2147/IJN.S405454. eCollection 2023.

Is Vitamin D Supplementation a Danger to Potential Treatments of Alzheimer's Disease Treatment?

Shih PY, Yong SB, Liu CM, Cheng-Chung Wei J.

Curr Alzheimer Res. 2023;20(2):59-62. doi: 10.2174/1567205020666230530095421.

Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer's disease

Javed B, Javed A, Kow CS, Hasan SS.

Expert Rev Neurother. 2023 Jun;23(6):501-514. doi: 10.1080/14737175.2023.2214316. Epub 2023 Jun 2.

Dysbiosis and Alzheimer's disease: role of probiotics, prebiotics and synbiotics

Thakkar A, Vora A, Kaur G, Akhtar J.

Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov;396(11):2911-2923. doi: 10.1007/s00210-023-02554-x. Epub 2023 Jun 7.

CRISPR-Cas9 in Alzheimer's disease: Therapeutic trends, modalities, and challenges

Chacko L, Chaudhary A, Singh B, Dewanjee S, Kandimalla R.

Drug Discov Today. 2023 Aug;28(8):103652. doi: 10.1016/j.drudis.2023.103652. Epub 2023 Jun 7.

Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development

Burns LH, Pei Z, Wang HY.

Drug Dev Res. 2023 Sep;84(6):1085-1095. doi: 10.1002/ddr.22085. Epub 2023 Jun 8.

Recent Mechanisms of Neurodegeneration and Photobiomodulation in the Context of Alzheimer's Disease

Su M, Nizamutdinov D, Liu H, Huang JH.

Int J Mol Sci. 2023 May 25;24(11):9272. doi: 10.3390/ijms24119272.

Advances of computer-aided drug design (CADD) in the development of anti-Azheimer's-disease drugs

Niu Y, Lin P.

Drug Discov Today. 2023 Aug;28(8):103665. doi: 10.1016/j.drudis.2023.103665. Epub 2023 Jun 9.

BACE-1 Inhibitors Targeting Alzheimer's Disease

Monteiro KLC, Dos Santos Alcântara MG, Freire NML, Brandão EM, do Nascimento VL, Dos Santos Viana LM, de Aquino TM, da Silva-Júnior EF.

Curr Alzheimer Res. 2023;20(3):131-148. doi: 10.2174/1567205020666230612155953.

Sex-based differences in effector cells of the adaptive immune system during Alzheimer's disease and related dementias

Lutshumba J, Wilcock DM, Monson NL, Stowe AM.

Neurobiol Dis. 2023 Aug;184:106202. doi: 10.1016/j.nbd.2023.106202. Epub 2023 Jun 15.

Crosstalk between Alzheimer's disease and diabetes: a focus on anti-diabetic drugs

Goodarzi G, Tehrani SS, Fana SE, Moradi-Sardareh H, Panahi G, Maniati M, Meshkani R.

Metab Brain Dis. 2023 Aug;38(6):1769-1800. doi: 10.1007/s11011-023-01225-3. Epub 2023 Jun 19.

siRNA drug delivery across the blood-brain barrier in Alzheimer's disease

Imran Sajid M, Sultan Sheikh F, Anis F, Nasim N, Sumbria RK, Nauli SM, Kumar Tiwari R.

Adv Drug Deliv Rev. 2023 Aug;199:114968. doi: 10.1016/j.addr.2023.114968. Epub 2023 Jun 21.

Editorial: What Is Reasonable and Necessary for Alzheimer Patients from Randomized Clinical Trials to Clinical Practice?

Middleton LT, Touchon J, Vellas B.

J Prev Alzheimers Dis. 2023;10(3):331-332. doi: 10.14283/jpad.2023.69.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias